Patent · US Active

AAV vectors

US12043848B2 · kind B2 · utility

0Cited by

3References

17Claims

0Family size

Assignee

Vigeneron GmbH · DE

Inventors

Stylianos Michalakis · Munich, DE
Martin Biel · Starnberg, DE
Christian Schön · Mietingen, DE
Hildegard BÜNING · Hannover, DE

Key dates

Filing date	Oct 16, 2018
Grant date	Jul 23, 2024
Priority date	—
Expiry date	Feb 18, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2810/40
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an adeno-associated virus (AAV), comprising an insertion of at least 6-8 amino acids between the positions corresponding to position 587 and 588 of SEQ ID NO: 1. Also envisioned are AAVs of the present invention for use as a medicament and pharmaceutical compositions comprising the AAV of the present invention. Further, the present invention relates to an in vitro use of AAV of the present invention for transduction of the nucleus of retinal cells. Also concerned is a method for screening an insertion sequence as well as a peptide obtainable by the method for screening. Also contemplated are kits comprising the AAV of the present invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.